Stockreport

Nefecon Included in the Updated KDIGO Clinical Practice Guideline, Strengthening Asahi Kasei’s Position in IgA Nephropathy Treatment

ASAHI KAISEI CRP UNSP/ADR  (AHKSY) 
NASDAQ:AMEX Investor Relations: asahi-kasei.co.jp/asahi/en/ir
PDF The final 2025 KDIGO Guideline suggests treatment with Nefecon should be considered in the majority of patients at risk of progressive loss of kidney function CHELMSF [Read more]